A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
News & Analysis: Puma Biotechnology
There are risks to having only one marketed drug product.
PBYI earnings call for the period ending March 31, 2019.
Investors reacted with dismay over the terms of a license agreement.
The pharma company announced full-year 2018 operating results and multiple business updates.
The terms of a new partnership aren't as good as investors had hoped.
Earnings momentum and some good business results sent these stocks up.
The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.
The company announced fourth-quarter and full-year 2018 earnings.
PBYI earnings call for the period ending December 31, 2018.